Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjunctive clindamycin for severe Staphylococcus aureus infection
ACTRN12617001416381Phase 4Recruiting
- Sponsor
- Menzies School of Health Research
- Start
- Jul 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of clindamycin in Staphylococcus aureus infection (2 arms), sponsored by Menzies School of Health Research. Primary endpoints: Days alive and free of systemic inflammatory response syndrome within 14 days and Feasibility. Started Jul 2018; status: recruiting.
02
Drugs
clindamycin
03
Conditions
Staphylococcus aureus infection
Beyond the preview
Go deeper on ACTRN12617001416381.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12617001416381.